La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Progress
06 août 2020 08h30 HE
|
La Jolla Pharmaceutical Company
SAN DIEGO, California, Aug. 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that...
Larry Edwards Appointed President and Chief Executive Officer of La Jolla Pharmaceutical Company
28 juil. 2020 16h16 HE
|
La Jolla Pharmaceutical Company
SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Board of Directors has appointed Larry Edwards as President and Chief Executive...
La Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, Inc.
28 juil. 2020 16h15 HE
|
La Jolla Pharmaceutical Company; Tetraphase Pharmaceuticals, Inc.
SAN DIEGO, California and WATERTOWN, Massachusetts, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of...
La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.
24 juin 2020 07h30 HE
|
La Jolla Pharmaceutical Company; Tetraphase Pharmaceuticals, Inc.
La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights Combined company will offer two innovative...
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2020
04 mai 2020 08h30 HE
|
La Jolla Pharmaceutical Company
SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes...
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Emergency Medical Program in Patients with Septic Shock Due to COVID-19 at CHIREC Delta Hospital, Brussels, Belgium
13 avr. 2020 08h30 HE
|
La Jolla Pharmaceutical Company
SAN DIEGO, April 13, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve...
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Münster in Germany
07 avr. 2020 08h30 HE
|
La Jolla Pharmaceutical Company
SAN DIEGO, April 07, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve...
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
06 avr. 2020 08h30 HE
|
La Jolla Pharmaceutical Company
SAN DIEGO, April 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve...
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Frankfurt in Germany
03 avr. 2020 08h30 HE
|
La Jolla Pharmaceutical Company
SAN DIEGO, April 03, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve...
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
02 avr. 2020 08h30 HE
|
La Jolla Pharmaceutical Company
SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve...